Tivozanib
- Generic Name
- Tivozanib
- Brand Names
- Fotivda
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClN4O5
- CAS Number
- 475108-18-0
- Unique Ingredient Identifier
- 172030934T
- Background
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapi...
- Indication
适用于治疗既往两种或多种全身治疗后复发或难治性晚期肾细胞癌（RCC）的成年患者。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
- Associated Therapies
- -
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1040
- Registration Number
- NCT06661720
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06053658
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 29
- Registration Number
- NCT05000294
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT04987203
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center - Monmouth - Oncology, Middletown, New Jersey, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Chao Family Comprehensive Cancer Center, UC Irvine, Irvine, California, United States
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT04645160
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03970616
- Locations
- 🇺🇸
University of California - Irvine, Orange, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03136627
- Locations
- 🇫🇷
Bordeaux Hospital University Center (CHU), Bordeaux, France
🇫🇷Center Léon Bérard, Lyon, France
🇫🇷Centre Paul Strauss, Strasbourg, France
Tivozanib As Maintenance Therapy In GYN
- Conditions
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT01972516
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Tivozanib + Enzalutamide in Adv Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01885949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 31
- Registration Number
- NCT01853644
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸CDH-Delnor Health System - Northwestern Medicine Cancer Center, Warrenville, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.